Edition:
India

Puma Biotechnology Inc (PBYI.OQ)

PBYI.OQ on NASDAQ Stock Exchange Global Select Market

91.60USD
19 Jan 2018
Change (% chg)

$3.35 (+3.80%)
Prev Close
$88.25
Open
$87.95
Day's High
$92.60
Day's Low
$87.95
Volume
177,674
Avg. Vol
223,509
52-wk High
$136.90
52-wk Low
$28.35

Chart for

About

Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous))... (more)

Overall

Beta: 0.85
Market Cap(Mil.): $4,516.76
Shares Outstanding(Mil.): 37.21
Dividend: --
Yield (%): --

Financials

BRIEF-Puma Biotechnology Intends To Modify Characteristics Summary In Neratinib Marketing Authorization Application

* PUMA BIOTECHNOLOGY INC SAYS IT MET WITH COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE SCIENTIFIC ADVISORY GROUP ON ONCOLOGY

12 Jan 2018

BRIEF-Daiichi Sankyo And Puma Biotechnology To Collaborate With Major Cancer Center In HER2-Mutated Cancer

* DAIICHI SANKYO AND PUMA BIOTECHNOLOGY ANNOUNCE RESEARCH COLLABORATION WITH MAJOR CANCER CENTER IN HER2-MUTATED CANCER Source text for Eikon: Further company coverage:

13 Dec 2017

BRIEF-Puma Biotechnology Announces Positive Outcome Of European Opposition Proceedings

* PUMA BIOTECHNOLOGY ANNOUNCES POSITIVE OUTCOME OF EUROPEAN OPPOSITION PROCEEDINGS

11 Dec 2017

BRIEF-PUMA BIOTECHNOLOGY, SPECIALISED THERAPEUTICS ASIA AGREE TO COMMERCIALIZE NERLYNX IN SOUTH EAST ASIA

* PUMA BIOTECHNOLOGY AND SPECIALISED THERAPEUTICS ASIA ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN AUSTRALIA, NEW ZEALAND AND SOUTH EAST ASIA

22 Nov 2017

BRIEF-Puma Biotechnology reports Q3 adj. loss per share $1.36

* Puma Biotechnology reports third quarter 2017 financial results

10 Nov 2017

BRIEF-Puma Biotechnology secures $100 mln term loan from Silicon Valley Bank and Oxford Finance

* Puma Biotechnology secures $100 million term loan from Silicon Valley Bank and Oxford Finance

03 Nov 2017

Former Puma Biotech executive pleads guilty to insider trading

BOSTON, Nov 2 A former Puma Biotechnology Inc executive pleaded guilty on Thursday to U.S. charges that he traded on inside information ahead of announcements by the biopharmaceutical company about a drug it was developing to treat breast cancer.

03 Nov 2017

BRIEF-Puma Biotechnology reports Q2 loss per share $2.10

* Puma Biotechnology reports second quarter 2017 financial results

10 Aug 2017

Earnings vs. Estimates